MedTrace Logo

Venetoclax Plus Inotuzumab for B-ALL

NCT05016947 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2026-01-29

No results posted yet for this study

Summary

This research study is evaluating the safety and efficacy of administering venetoclax and inotuzumab ozogamicin in combination in patients with acute lymphoblastic leukemia (ALL)

The names of the study drugs involved in this study are:

* Venetoclax
* Inotuzumab ozogamicin
* Dexamethasone

Conditions

Interventions

DRUG

Venetoclax

Tablet, taken by mouth

DRUG

Dexamethasone

Taken orally

DRUG

Inotuzumab Ozogamicin

Intravenous infusion

Sponsors & Collaborators

Principal Investigators

  • Marlise R Luskin, MD, MSCE · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-24
Primary Completion
2023-07-10
Completion
2026-12-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05016947 on ClinicalTrials.gov